S&P 500   3,426.92 (-1.63%)
DOW   28,195.42 (-1.44%)
QQQ   283.80 (-1.63%)
AAPL   115.98 (-2.55%)
MSFT   214.22 (-2.48%)
FB   261.40 (-1.70%)
GOOGL   1,529.95 (-2.41%)
AMZN   3,207.21 (-2.00%)
TSLA   430.83 (-2.01%)
NVDA   539.91 (-2.27%)
BABA   305.29 (-0.66%)
CGC   19.81 (+11.54%)
GE   7.29 (+0.00%)
MU   52.63 (+1.98%)
AMD   82.00 (-1.41%)
T   26.88 (-1.65%)
F   7.59 (-1.04%)
ACB   4.71 (+17.16%)
GILD   60.57 (-2.31%)
NFLX   530.72 (-0.01%)
BA   167.11 (-0.14%)
BAC   23.72 (-2.15%)
DIS   124.23 (-2.03%)
S&P 500   3,426.92 (-1.63%)
DOW   28,195.42 (-1.44%)
QQQ   283.80 (-1.63%)
AAPL   115.98 (-2.55%)
MSFT   214.22 (-2.48%)
FB   261.40 (-1.70%)
GOOGL   1,529.95 (-2.41%)
AMZN   3,207.21 (-2.00%)
TSLA   430.83 (-2.01%)
NVDA   539.91 (-2.27%)
BABA   305.29 (-0.66%)
CGC   19.81 (+11.54%)
GE   7.29 (+0.00%)
MU   52.63 (+1.98%)
AMD   82.00 (-1.41%)
T   26.88 (-1.65%)
F   7.59 (-1.04%)
ACB   4.71 (+17.16%)
GILD   60.57 (-2.31%)
NFLX   530.72 (-0.01%)
BA   167.11 (-0.14%)
BAC   23.72 (-2.15%)
DIS   124.23 (-2.03%)
S&P 500   3,426.92 (-1.63%)
DOW   28,195.42 (-1.44%)
QQQ   283.80 (-1.63%)
AAPL   115.98 (-2.55%)
MSFT   214.22 (-2.48%)
FB   261.40 (-1.70%)
GOOGL   1,529.95 (-2.41%)
AMZN   3,207.21 (-2.00%)
TSLA   430.83 (-2.01%)
NVDA   539.91 (-2.27%)
BABA   305.29 (-0.66%)
CGC   19.81 (+11.54%)
GE   7.29 (+0.00%)
MU   52.63 (+1.98%)
AMD   82.00 (-1.41%)
T   26.88 (-1.65%)
F   7.59 (-1.04%)
ACB   4.71 (+17.16%)
GILD   60.57 (-2.31%)
NFLX   530.72 (-0.01%)
BA   167.11 (-0.14%)
BAC   23.72 (-2.15%)
DIS   124.23 (-2.03%)
S&P 500   3,426.92 (-1.63%)
DOW   28,195.42 (-1.44%)
QQQ   283.80 (-1.63%)
AAPL   115.98 (-2.55%)
MSFT   214.22 (-2.48%)
FB   261.40 (-1.70%)
GOOGL   1,529.95 (-2.41%)
AMZN   3,207.21 (-2.00%)
TSLA   430.83 (-2.01%)
NVDA   539.91 (-2.27%)
BABA   305.29 (-0.66%)
CGC   19.81 (+11.54%)
GE   7.29 (+0.00%)
MU   52.63 (+1.98%)
AMD   82.00 (-1.41%)
T   26.88 (-1.65%)
F   7.59 (-1.04%)
ACB   4.71 (+17.16%)
GILD   60.57 (-2.31%)
NFLX   530.72 (-0.01%)
BA   167.11 (-0.14%)
BAC   23.72 (-2.15%)
DIS   124.23 (-2.03%)
Log in
NASDAQ:NKTR

Nektar Therapeutics Stock Forecast, Price & News

$16.87
-0.27 (-1.58 %)
(As of 10/19/2020 12:00 AM ET)
Add
Compare
Today's Range
$16.77
Now: $16.87▼
$17.34
50-Day Range
$16.28
MA: $18.42▼
$20.34
52-Week Range
$13.63
Now: $16.87▼
$28.60
Volume742,351 shs
Average Volume1.41 million shs
Market Capitalization$3.02 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.82
Nektar Therapeutics, a biopharmaceutical company, researches and develops drug candidates for cancer and auto-immune disease in the United States. The company develops NKTR-181, a novel mu-opioid analgesic drug, which is in Phase III clinical trial for chronic low back pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I is designed to provide rapid activation and proliferation of cancer-killing CD8+ effector T cells and NK cells. It also develops NKTR-358, cytokine Treg stimulant, which is in Phase I to treat autoimmune diseases; NKTR-262, a toll-like receptor agonist that is in Phase I for oncology; and NKTR-255, which is in phase I for immuno-oncology. In addition, the is developing ADYNOVATE and ADYNOVI for hemophilia A; MOVANTIK for opioid-induced constipation in adult patients with chronic non-cancer pain; CIMZIA for crohn's disease, rheumatoid arthritis, and psoriasis/ankylosing spondylitis; and MIRCERA for anemia associated with chronic kidney disease. Further, it is developing Macugen for age-related macular degeneration; Somavert for acromegaly; Neulasta for neutropenia; Dapirolizumab Pegol for systemic lupus erythematosus; PEGPH20 for pancreatic, non-small cell lung cancer, and other tumor types; and longer-acting blood clotting proteins for hemophilia. The company has collaboration agreement with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Halozyme Therapeutics, Inc.; Bristol-Myers Squibb Company; Baxalta Incorporated; and Eli Lilly and Company, as well as with Merck KGaA. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.
Read More
Nektar Therapeutics logo

Beat the Market (BTM) Rank™

Analyst Opinion: 3.3Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.45 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:NKTR
Previous Symbol
CUSIP64026810
CIK906709
Webwww.nektar.com
Phone415-482-5300
Employees723

Debt

Debt-to-Equity RatioN/A
Current Ratio9.29
Quick Ratio9.19

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$114.62 million
Price / Sales26.33
Cash FlowN/A
Price / Cash FlowN/A
Book Value$7.99 per share
Price / Book2.11

Profitability

EPS (Most Recent Fiscal Year)($2.52)
Net Income$-440,670,000.00
Net Margins-264.38%
Return on Equity-28.23%
Return on Assets-20.37%

Miscellaneous

Outstanding Shares178,900,000
Market Cap$3.02 billion
Next Earnings Date11/4/2020 (Estimated)
OptionableOptionable
$16.87
-0.27 (-1.58 %)
(As of 10/19/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NKTR News and Ratings via Email

Sign-up to receive the latest news and ratings for NKTR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Nektar Therapeutics (NASDAQ:NKTR) Frequently Asked Questions

How has Nektar Therapeutics' stock been impacted by Coronavirus (COVID-19)?

Nektar Therapeutics' stock was trading at $16.47 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, NKTR shares have increased by 2.4% and is now trading at $16.87.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Nektar Therapeutics?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nektar Therapeutics in the last year. There are currently 1 sell rating, 5 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Nektar Therapeutics.

When is Nektar Therapeutics' next earnings date?

Nektar Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Nektar Therapeutics.

How were Nektar Therapeutics' earnings last quarter?

Nektar Therapeutics (NASDAQ:NKTR) released its quarterly earnings data on Thursday, August, 6th. The biopharmaceutical company reported ($0.45) earnings per share for the quarter, topping analysts' consensus estimates of ($0.69) by $0.24. The biopharmaceutical company had revenue of $48.85 million for the quarter, compared to the consensus estimate of $22.76 million. Nektar Therapeutics had a negative net margin of 264.38% and a negative return on equity of 28.23%. The firm's quarterly revenue was up 109.5% on a year-over-year basis. During the same period in the prior year, the business earned ($0.63) EPS.
View Nektar Therapeutics' earnings history.

What price target have analysts set for NKTR?

15 analysts have issued 1-year price targets for Nektar Therapeutics' shares. Their forecasts range from $17.00 to $80.00. On average, they expect Nektar Therapeutics' stock price to reach $31.23 in the next twelve months. This suggests a possible upside of 85.1% from the stock's current price.
View analysts' price targets for Nektar Therapeutics.

Who are some of Nektar Therapeutics' key competitors?

Some companies that are related to Nektar Therapeutics include Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Eli Lilly And Co (LLY), Zoetis (ZTS), Horizon Therapeutics Public (HZNP), Royalty Pharma (RPRX), Jazz Pharmaceuticals (JAZZ), Mylan (MYL), Perrigo (PRGO), Pacira Biosciences (PCRX), Corcept Therapeutics (CORT) and Endo International (ENDP).
View all competitors.

What other stocks do shareholders of Nektar Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nektar Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Gilead Sciences (GILD), Intel (INTC), Pfizer (PFE), Advanced Micro Devices (AMD), Bristol-Myers Squibb (BMY), Netflix (NFLX) and Incyte (INCY).

Who are Nektar Therapeutics' key executives?

Nektar Therapeutics' management team includes the following people:
  • Mr. Howard W. Robin, CEO, Pres & Director (Age 67, Pay $1.19M)
  • Mr. Gilbert M. Labrucherie, Sr. VP, CFO & COO (Age 48, Pay $695.82k)
  • Ms. Jillian B. Thomsen, Sr. VP of Fin. & Chief Accounting Officer (Age 54, Pay $470.79k)
  • Dr. Jonathan Zalevsky, Chief R&D Officer (Age 45, Pay $590.12k)
  • Mr. John P. Northcott, Sr. VP & Chief Commercial Officer (Age 42, Pay $269.56k)

What is Nektar Therapeutics' stock symbol?

Nektar Therapeutics trades on the NASDAQ under the ticker symbol "NKTR."

Who are Nektar Therapeutics' major shareholders?

Nektar Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Rhenman & Partners Asset Management AB (0.56%), Assenagon Asset Management S.A. (0.11%), DAVENPORT & Co LLC (0.03%), Pacer Advisors Inc. (0.02%), Private Asset Management Inc. (0.02%) and State of Alaska Department of Revenue (0.02%). Company insiders that own Nektar Therapeutics stock include Gil M Labrucherie, Howard W Robin, Jeffrey Robert Ajer, Jillian B Thomsen, John Nicholson, Jonathan Zalevsky, Katharina Otto-Bernstein, Lutz Lingnau, Maninder Hora, Mark Andrew Wilson, R Scott Greer, Robert Chess and Stephen K Doberstein.
View institutional ownership trends for Nektar Therapeutics.

Which institutional investors are selling Nektar Therapeutics stock?

NKTR stock was sold by a variety of institutional investors in the last quarter, including DAVENPORT & Co LLC, and State of Alaska Department of Revenue. Company insiders that have sold Nektar Therapeutics company stock in the last year include Gil M Labrucherie, Howard W Robin, Jeffrey Robert Ajer, Jillian B Thomsen, Jonathan Zalevsky, Mark Andrew Wilson, R Scott Greer, and Robert Chess.
View insider buying and selling activity for Nektar Therapeutics.

Which institutional investors are buying Nektar Therapeutics stock?

NKTR stock was bought by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Assenagon Asset Management S.A., Pacer Advisors Inc., Ropes Wealth Advisors LLC, Avantax Advisory Services Inc., Contravisory Investment Management Inc., and Private Asset Management Inc..
View insider buying and selling activity for Nektar Therapeutics.

How do I buy shares of Nektar Therapeutics?

Shares of NKTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Nektar Therapeutics' stock price today?

One share of NKTR stock can currently be purchased for approximately $16.87.

How big of a company is Nektar Therapeutics?

Nektar Therapeutics has a market capitalization of $3.02 billion and generates $114.62 million in revenue each year. The biopharmaceutical company earns $-440,670,000.00 in net income (profit) each year or ($2.52) on an earnings per share basis. Nektar Therapeutics employs 723 workers across the globe.

What is Nektar Therapeutics' official website?

The official website for Nektar Therapeutics is www.nektar.com.

How can I contact Nektar Therapeutics?

Nektar Therapeutics' mailing address is 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158. The biopharmaceutical company can be reached via phone at 415-482-5300 or via email at [email protected]

This page was last updated on 10/19/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.